Sunshine Insurance participated in a $70.7m round for the contract biopharmaceutical services provider that follows $59m last year.
China-based pharmaceutical services provider MabPlex International has secured more than RMB500m ($70.7m) in a series B round backed by insurance group Sunshine Insurance, DealStreetAsia reported today, citing a WeChat post.
DT Capital Partners and Huajin Capital co-led the round, which included OrbiMed, China Merchants Securities, Finnova Capital, Horus Capital, Qiandao Fund, GF Venture Capital, Yantai Finance Investment Group, Huachen Equity Investment Management and SDIC Venture Capital.
Founded in 2013, MabPlex provides contract biopharmaceutical development and manufacturing services through sites in…
